Simufilam (PTI-125) is a low toxicity, orally active filamin A (FLNA) activator. Simufilam preferentially binds altered FLNA and restores its native conformation, restores receptor and synaptic activities, reduces its a7nAChR/TLR4 associations and downstream pathologies. Simufilam can be used for the research of Alzheimer’s disease[1].
Simufilam (1 pM~1 nM) dose-dependently improves NMDA/glycine-induced Arc expression[1].Simufilam (1 nM, 1 hour) largely restores filamin A to its native conformation and is effective in normalizing receptor activities in AD frontal cortices. Simufilam dose-dependently reduces Ab42-induced FLNA coupling to a7nAChR and TLR4 in both Ab42-treated control and AD hippocampus. Simufilam reduces Ab42’s binding affinity for a7nAChR, thereby prevents Ab42’s signaling and further accumulation on a7nAChRs[1].
Simufilam (P.o.; 2 months) restores FLNA to its native conformation. Simufilam (22 mg/kg; p.o.) robustly reduces FLNAea7nAChR/TLR4 associations. Simufilam significantly improves spatial memory. Simufilam significantly improves working memory[1].
[1]. Wang HY, et al. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer’s disease pathogenesis. Neurobiol Aging. 2017;55:99-114.